Frontlight ResearchEarly access
CompletedPhase 3
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
Key facts
- Who runs it
- Epion Therapeutics
- Where
- Aurora, Austin, Charlotte, Draper, Highland Park, Memphis, Murrieta, Norfolk, North Dartmouth, Omaha, Scottsdale, and Tucson, United StatesSee the 12 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 398 people enrolled
- Started
- 1 Nov 2023
- Ended
- 17 Mar 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment
- Placebo and sham treatment
- Record updated
- 25 June 2026
Who can take part
- Age
- 8 years to 45 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Diagnosis of keratoconus
Who cannot take part
- Contraindications or hypersensitivities to any required study medications
- Certain concomitant ocular conditions
- Non-keratoconic ectatic disease
- Minimal corneal thickness < 350 microns
- Pregnancy or breastfeeding
Where in United States
- University of ColoradoAurora, United States
- Dell Laser ConsultantsAustin, United States
- Providence Eye and Laser SpecialistsCharlotte, United States
- Hoopes VisionDraper, United States
- Chicago Cornea ConsultantsHighland Park, United States
- VRF Eye Specialty GroupMemphis, United States
- Inland Eye SpecialistsMurrieta, United States
- Virginia Eye ConsultantsNorfolk, United States
- Claris Vision LLC Eye Health Vision Centers - DartmouthNorth Dartmouth, United States
- Truhlsen Eye InstituteOmaha, United States
- Schwartz Laser Eye CenterScottsdale, United States
- Catalina Eye CenterTucson, United States
About the trial
What the trial wants to find out
A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
The 2 groups in the trial
- Active TreatmentTreatment being tested
Epithelium-on corneal cross-linking
Treatment: Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment
- Control TreatmentPlacebo, for comparison
Placebo and sham for epithelium-on corneal cross-linking
Treatment: Placebo and sham treatment
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus (APRICITY-B)
- Record updated
- 25 June 2026